JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

JCAD-Derived from Plasma Exosomes: Promoting Tumor Cell Progression and Predicting Poor Outcomes in Breast Cancer

  • 0Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
International Journal of Biological Sciences +

|

August 27, 2025

|

August 27, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Exosomal JCAD shows promise as a biomarker for breast cancer prognosis. This study identified key genes in exosomes to predict patient outcomes, aiding in diagnosis and treatment strategies.

Area Of Science

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background

  • Breast cancer is the most common cancer in women, with prognosis heavily dependent on disease stage.
  • Exosomes in liquid biopsy samples contain key genes that may serve as prognostic biomarkers.
  • Identifying reliable biomarkers is crucial for predicting breast cancer patient outcomes.

Purpose Of The Study

  • To identify and validate exosomal genes as prognostic biomarkers for breast cancer.
  • To develop a prognostic model for breast cancer using transcriptome sequencing data.
  • To investigate the role of JCAD in breast cancer progression.

Main Methods

  • Transcriptome sequencing of 128 breast cancer patient blood samples for training data.
  • LASSO regression analysis to screen prognostic genes and build a model.
  • Validation using an independent cohort of 131 patient samples and functional assays.

Main Results

  • Eleven differentially expressed genes correlated with breast cancer stage were identified.
  • A five-gene prognostic model demonstrated high predictive accuracy (AUC 0.858 for 1-year, 0.772 for 2-year).
  • Exosomal JCAD promotes breast cancer progression via the Wnt/β-catenin pathway by upregulating FZD1.

Conclusions

  • Exosomal JCAD is a significant prognostic marker for breast cancer.
  • The identified prognostic model shows potential for clinical application in diagnosis and treatment.
  • Targeting the JCAD-mediated pathway could offer new therapeutic strategies for breast cancer.

Keywords:

Related Concept Videos

Metastasis 02:30

5.7K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Tumor Progression 02:07

6.5K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Adaptive Mechanisms in Cancer Cells 02:53

5.9K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

The Tumor Microenvironment 02:17

6.8K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

mTOR Signaling and Cancer Progression 03:03

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer Stem Cells and Tumor Maintenance 02:40

5.0K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...